TLR4 and atherosclerosis: Signalling caused by PAMPs or their derivatives formed during processing may stimulate innate Toll-like receptors (TLR2 and TLR4), leading to strong immune reactions associated with inflammation, type 2 diabetes, atherosclerosis, and increased cardiometabolic risk factors [84].